REG - AIM - Schedule One Update - Optima Health PLC

Ameriprise FinancialAnnouncement

23/09/2024 09:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240923:nRSW1132Fa&default-theme=true

RNS Number : 1132F  AIM  23 September 2024

 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE
 WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES")

 COMPANY NAME:

 Optima Health Limited (to be renamed Optima Health plc)

 ("Optima" or the "Company")

 COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS
 (INCLUDING POSTCODES) :

 Meadow Court,

 2 Hayland Street,

 Sheffield,

 United Kingdom

 S9 1BY

 COUNTRY OF INCORPORATION:

 England and Wales

 COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26:

 www.optimahealth.co.uk (http://www.optimahealth.co.uk)

 COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN
 INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY).  IF THE ADMISSION IS
 SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE
 STATED:

 Optima comprises the Occupational Health division which will be demerged from
 Marlowe plc ahead of Admission.

 Optima is the UK's leading provider of technology enabled corporate health and
 wellbeing solutions in the occupational health sector, a specialist branch of
 medicine, with an addressable UK market value of approximately £1.2 billion
 as at 2023. Underpinned by a robust clinical governance framework, the Group
 (being the Company and its subsidiary undertakings) leverages its proprietary
 technology and flexible delivery platform to foster healthy high performance
 within its clients' workforces. The Group offers a comprehensive range of
 flexible and progressive services from statutory driven workplace health
 surveillance medicals to proactive and preventive interventions, through to
 workplace health advice and attendance management assessments, and ultimately
 rehabilitation programmes and pathways aimed at returning people to work.

 Operating a B2B business model, the Group currently services a well-balanced
 portfolio of more than 2,000 public sector and private sector clients across
 the UK. Clients typically have a consistent demand profile and operate in
 industries such as logistics, rail and transport, blue light / NHS,
 manufacturing and construction, financial services, retail and central and
 local government.

 Through the Group's integrated model and nationwide coverage, delivery of its
 services is facilitated via several channels, both remotely and on-site.
 Across the UK, Optima has an extensive network comprising seven core hubs, a
 nationwide network of 48 occupational health clinics and mobile clinic
 solutions, with services delivered by a team of over 800 directly employed
 clinicians in the UK, across a wide range of disciplines. In addition, Optima
 has a network of over 1,000 subcontracted associate clinicians providing
 resource flexibility to align with client needs.

 DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER
 OF THE SECURITIES (i.e. where known, number and type of shares, nominal value
 and issue price to which it seeks admission and the number and type to be held
 as treasury shares):

 88,776,226 Ordinary Shares of £0.01 each

 There are no shares to be held as treasury shares and there are no
 restrictions as to

 transfer of the securities.

 CAPITAL TO BE RAISED ON ADMISSION (AND/OR SECONDARY OFFERING) AND ANTICIPATED
 MARKET CAPITALISATION ON ADMISSION:

 Capital to be raised on Admission: n/a

 Anticipated market capitalisation on Admission: approximately £190 million

 PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:

 Approximately 17.5 per cent. of the issued share capital not in public hands
 on Admission

 DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES
 (OR OTHER SECURITIES OF THE COMPANY) ARE OR WILL BE ADMITTED OR TRADED:

 N/A

 THE COMPANY HAS APPLIED FOR THE VOLUNTARY CARBON MARKET DESIGNATION (Y/N)

 N

 FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the
 first name by which each is known or including any other name by which each is
 known):
 On Admission:

 Julia Robertson - Non-Executive Chair

 Jonathan David Thomas - Chief Executive Officer

 Heidi Samsara Giles - Chief Financial Officer

 Adam Thomas Councell - Non-Executive Director

 Simon Ashley Arnold - Non-Executive Director

 Michael (Mike) Ernest Ettling - Non-Executive Director

 FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE
 OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first
 name by which each is known or including any other name by which each is
 known):
 So far as the Company is aware, the significant shareholders and their
 respective interests in the Company's share capital on Admission are:

Shareholder                        % holding
 Lord Michael Ashcroft              17.2
 Slater Investments                 8.0
 Octopus Investments                5.7
 Capital Research Global Investors  4.8
 Columbia Threadneedle              3.3
 Fidelity                           3.1
 NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH
 (H) OF THE AIM RULES:

 N/A

 (i)         ANTICIPATED ACCOUNTING REFERENCE DATE

 (ii)        DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE
 ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited
 interim financial information)

 (iii)       DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS
 PURSUANT TO AIM RULES 18 AND 19:
 (i)         31 March

 (ii)        Audited results for the 12 months to 31 March 2024

 (iii)       31 December 2024 (unaudited results for the 6 months to 30
 September 2024)

 (iii)       30 September 2025 (audited results for the 12 months to 31
 March 2025)

 (iii)       31 December 2025 (unaudited results for the 6 months to 30
 September 2025)

 EXPECTED ADMISSION DATE:

 26 September 2024

 NAME AND ADDRESS OF NOMINATED ADVISER:

 Panmure Liberum Limited

 Ropemaker Place, Level 12

 25 Ropemaker Street

 London EC2Y 9LY

 NAME AND ADDRESS OF BROKER:

 Panmure Liberum Limited

 Ropemaker Place, Level 12

 25 Ropemaker Street

 London EC2Y 9LY

 OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR
 INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A
 STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE
 ADMISSION OF ITS SECURITIES:

 The Admission Document, which will contain full details about the applicant
 and the admission of its securities, will be available on the Company's
 website (www.optimahealth.co.uk (http://www.optimahealth.co.uk) ) from the
 date of the Company's admission.

 THE CORPORATE GOVERNANCE CODE THE APPLICANT HAS DECIDED TO APPLY

 QCA Corporate Governance Code

 DATE OF NOTIFICATION:

 23 September 2024

 NEW/ UPDATE:

 Update

NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH
(H) OF THE AIM RULES:

 

N/A

 

(i)         ANTICIPATED ACCOUNTING REFERENCE DATE

(ii)        DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE
ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited
interim financial information)

(iii)       DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS
PURSUANT TO AIM RULES 18 AND 19:

(i)         31 March

(ii)        Audited results for the 12 months to 31 March 2024

(iii)       31 December 2024 (unaudited results for the 6 months to 30
September 2024)

(iii)       30 September 2025 (audited results for the 12 months to 31
March 2025)

(iii)       31 December 2025 (unaudited results for the 6 months to 30
September 2025)

 

EXPECTED ADMISSION DATE:

 

26 September 2024

 

NAME AND ADDRESS OF NOMINATED ADVISER:

 

Panmure Liberum Limited

Ropemaker Place, Level 12

25 Ropemaker Street

London EC2Y 9LY

 

NAME AND ADDRESS OF BROKER:

 

Panmure Liberum Limited

Ropemaker Place, Level 12

25 Ropemaker Street

London EC2Y 9LY

 

OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR
INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A
STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE
ADMISSION OF ITS SECURITIES:

 

The Admission Document, which will contain full details about the applicant
and the admission of its securities, will be available on the Company's
website (www.optimahealth.co.uk (http://www.optimahealth.co.uk) ) from the
date of the Company's admission.

 

THE CORPORATE GOVERNANCE CODE THE APPLICANT HAS DECIDED TO APPLY

 

QCA Corporate Governance Code

 

DATE OF NOTIFICATION:

 

23 September 2024

 

NEW/ UPDATE:

 

Update

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AIMSELFISELSEEU